Cardia Bioplastics,a global developer and manufacturer of sustainable resins derived from renewable resources, has expanded its patent portfolio to nineteen patents granted with fourty two more pending registration.
The company, which was established in Australia and has operations in the Americas, Europe, Australia and Asia, said seven new patents for its Cardia Compostable, Biohybrid and PPC-starch technology had been granted in Japan, Australia, New Zealand and China in 2014.
These new patents expand Cardia Bioplastics growing intellectual property portfolio of 11 patent families, with 19 patents so far granted in USA, Australia, China, Japan, New Zealand and South Africa. The patents protect the composition formulation and manufacturing process invented by Cardia’s RD team.
On receiving the news, Dr Frank Glatz, managing director of Cardia Bioplastics said: “This marks an important milestone for Cardia Bioplastics. These granted patents protect the intellectual property of the Company and further support the technical differentiation of our globally certified Cardia Compostable and independently validated lower carbon foot print Cardia Biohybrid product offering.”
“Cardia is collaborating with leading global brand owners to reduce the environmental impact of their packaging. Cardia’s Biohybrid technology enables them to reduce the carbon footprint and the use of less oil in their packaging with an environmental benefit whilst maintaining product performance.”
Established in Australia in 2002, the company Headquarters and Global Application Development Centre is in Melbourne, Australia. Cardia Bioplastics’ Product Development Centre and manufacturing plant for resins is in Nanjing, China. Cardia’s manufacturing plants for film and bag products are in Nanjing, China and São Paulo, Brazil.
Cardia was the exclusive supplier of biodegradable packaging to the 2008 Beijing Olympic and Paralympic Games and was awarded the Australian Chamber of Commerce ‘Australia-China Business Excellence Award’ in 2008.